These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

385 related items for PubMed ID: 24995467

  • 1. Expression of DNA mismatch repair proteins MLH1, MSH2, and MSH6 in recurrent glioblastoma.
    Stark AM, Doukas A, Hugo HH, Hedderich J, Hattermann K, Maximilian Mehdorn H, Held-Feindt J.
    Neurol Res; 2015 Feb; 37(2):95-105. PubMed ID: 24995467
    [Abstract] [Full Text] [Related]

  • 2. The expression of mismatch repair proteins MLH1, MSH2 and MSH6 correlates with the Ki67 proliferation index and survival in patients with recurrent glioblastoma.
    Stark AM, Doukas A, Hugo HH, Mehdorn HM.
    Neurol Res; 2010 Oct; 32(8):816-20. PubMed ID: 20223108
    [Abstract] [Full Text] [Related]

  • 3. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas.
    Felsberg J, Thon N, Eigenbrod S, Hentschel B, Sabel MC, Westphal M, Schackert G, Kreth FW, Pietsch T, Löffler M, Weller M, Reifenberger G, Tonn JC, German Glioma Network.
    Int J Cancer; 2011 Aug 01; 129(3):659-70. PubMed ID: 21425258
    [Abstract] [Full Text] [Related]

  • 4. The role of MLH1, MSH2 and MSH6 in the development of multiple colorectal cancers.
    Lawes DA, Pearson T, Sengupta S, Boulos PB.
    Br J Cancer; 2005 Aug 22; 93(4):472-7. PubMed ID: 16106253
    [Abstract] [Full Text] [Related]

  • 5. Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastoma.
    Ganesa S, Sule A, Sundaram RK, Bindra RS.
    Sci Rep; 2022 Apr 06; 12(1):5827. PubMed ID: 35388070
    [Abstract] [Full Text] [Related]

  • 6. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.
    Cao VT, Jung TY, Jung S, Jin SG, Moon KS, Kim IY, Kang SS, Park CS, Lee KH, Chae HJ.
    Neurosurgery; 2009 Nov 06; 65(5):866-75; discussion 875. PubMed ID: 19834398
    [Abstract] [Full Text] [Related]

  • 7. Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 protein expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients.
    Nakai K, Mitomi H, Alkam Y, Arakawa A, Yao T, Tokuda E, Saito M, Kasumi F.
    Cancer Chemother Pharmacol; 2012 Apr 06; 69(4):923-30. PubMed ID: 22083523
    [Abstract] [Full Text] [Related]

  • 8. Immunohistochemical staining for DNA mismatch repair proteins in intestinal tract carcinoma: how reliable are biopsy samples?
    Shia J, Stadler Z, Weiser MR, Rentz M, Gonen M, Tang LH, Vakiani E, Katabi N, Xiong X, Markowitz AJ, Shike M, Guillem J, Klimstra DS.
    Am J Surg Pathol; 2011 Mar 06; 35(3):447-54. PubMed ID: 21297438
    [Abstract] [Full Text] [Related]

  • 9. Prognostic significance of DNA repair proteins MLH1, MSH2 and MGMT expression in non-small-cell lung cancer and precursor lesions.
    Cooper WA, Kohonen-Corish MR, Chan C, Kwun SY, McCaughan B, Kennedy C, Sutherland RL, Lee CS.
    Histopathology; 2008 Apr 06; 52(5):613-22. PubMed ID: 18370958
    [Abstract] [Full Text] [Related]

  • 10. Immunohistochemistry and microsatellite instability testing for selecting MLH1, MSH2 and MSH6 mutation carriers in hereditary non-polyposis colorectal cancer.
    Caldés T, Godino J, Sanchez A, Corbacho C, De la Hoya M, Lopez Asenjo J, Saez C, Sanz J, Benito M, Ramon Y Cajal S, Diaz-Rubio E.
    Oncol Rep; 2004 Sep 06; 12(3):621-9. PubMed ID: 15289847
    [Abstract] [Full Text] [Related]

  • 11. Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells.
    Koutsimpelas D, Pongsapich W, Heinrich U, Mann S, Mann WJ, Brieger J.
    Oncol Rep; 2012 Apr 06; 27(4):1135-41. PubMed ID: 22246327
    [Abstract] [Full Text] [Related]

  • 12. Expression of DNA repair proteins MSH2, MLH1 and MGMT in human benign and malignant thyroid lesions: an immunohistochemical study.
    Giaginis C, Michailidi C, Stolakis V, Alexandrou P, Tsourouflis G, Klijanienko J, Delladetsima I, Theocharis S.
    Med Sci Monit; 2011 Feb 25; 17(3):BR81-90. PubMed ID: 21358597
    [Abstract] [Full Text] [Related]

  • 13. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
    Kim BS, Kong DS, Seol HJ, Nam DH, Lee JI.
    J Neurooncol; 2017 Jul 25; 133(3):615-622. PubMed ID: 28536992
    [Abstract] [Full Text] [Related]

  • 14. EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma.
    Struve N, Binder ZA, Stead LF, Brend T, Bagley SJ, Faulkner C, Ott L, Müller-Goebel J, Weik AS, Hoffer K, Krug L, Rieckmann T, Bußmann L, Henze M, Morrissette JJD, Kurian KM, Schüller U, Petersen C, Rothkamm K, O Rourke DM, Short SC, Kriegs M.
    Oncogene; 2020 Apr 25; 39(15):3041-3055. PubMed ID: 32066879
    [Abstract] [Full Text] [Related]

  • 15. Expression of DNA repair proteins, MSH2, MLH1 and MGMT in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients' survival.
    Theocharis S, Klijanienko J, Giaginis C, Rodriguez J, Jouffroy T, Girod A, Point D, Tsourouflis G, Sastre-Garau X.
    J Oral Pathol Med; 2011 Mar 25; 40(3):218-26. PubMed ID: 21029181
    [Abstract] [Full Text] [Related]

  • 16. Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.
    Nguyen SA, Stechishin OD, Luchman HA, Lun XQ, Senger DL, Robbins SM, Cairncross JG, Weiss S.
    Clin Cancer Res; 2014 Sep 15; 20(18):4894-903. PubMed ID: 25078279
    [Abstract] [Full Text] [Related]

  • 17. Expression and methylation status of MMR and MGMT in well-differentiated pancreatic neuroendocrine tumors and potential clinical applications.
    Ban X, Mo S, Lu Z, Jia C, Shao H, Chang X, Mao X, Zhang Y, Pang J, Zhang Y, Yu S, Chen J.
    Endocrine; 2022 Sep 15; 77(3):538-545. PubMed ID: 35708896
    [Abstract] [Full Text] [Related]

  • 18. Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancer.
    Backes FJ, Leon ME, Ivanov I, Suarez A, Frankel WL, Hampel H, Fowler JM, Copeland LJ, O'Malley DM, Cohn DE.
    Gynecol Oncol; 2009 Sep 15; 114(3):486-90. PubMed ID: 19515405
    [Abstract] [Full Text] [Related]

  • 19. Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma.
    Hall G, Clarkson A, Shi A, Langford E, Leung H, Eckstein RP, Gill AJ.
    Pathology; 2010 Sep 15; 42(5):409-13. PubMed ID: 20632815
    [Abstract] [Full Text] [Related]

  • 20. Protein expression and methylation of DNA repair genes hMLH1, hMSH2, MGMT and BRCA1 and their correlation with clinicopathological parameters and prognosis in basal-like breast cancer.
    Alkam Y, Mitomi H, Nakai K, Himuro T, Saito T, Takahashi M, Arakawa A, Yao T, Saito M.
    Histopathology; 2013 Nov 15; 63(5):713-25. PubMed ID: 24004112
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.